Fingolimod 0.5mg

( DrugBank: Fingolimod / KEGG DRUG: Fingolimod )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	6

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 6 of 6 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04667949 (ClinicalTrials.gov)	February 20, 2021	8/12/2020	Study of Efficacy and Safety of Fingolimod(Gilenya) 0.5 mg in Chinese Patients With Relapsing Multip ...	A 24-month, Open-label, Prospective, Multicenter Interventional, Single-arm Study Assessing the Effi ...	Relapsing Multiple Sclerosis (RMS)	Drug: Fingolimod 0.5mg	Novartis Pharmaceuticals	NULL	Recruiting	10 Years	65 Years	All	100	Phase 4	China
2	JPRN-JapicCTI-194838	31/7/2019	02/07/2019	Investigation for immune response against JC virus in Multiple Sclerosis patients on treatment with ...	A 18-month, multicenter, two-cohort, prospective, observational study to investigate immune response ...	Multiple Sclerosis	Intervention name : Gilenya / Imusera INN of the intervention : Fingolimod Dosage And administration o ...	Novartis Pharma K.K.	Mitsubishi Tanabe Pharma Corporation	complete	18		BOTH	280	NA	Japan
3	NCT03257358 (ClinicalTrials.gov)	September 19, 2017	18/8/2017	A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Tre ...	A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients ...	Relapsing Multiple Sclerosis	Drug: Fingolimod	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	382	Phase 4	United States
4	NCT02048072 (ClinicalTrials.gov)	July 2013	27/1/2014	Evaluation of the Autonomic Nervous System During First-dosing With 0.5mgof Fingolimod(Gilenya) in P ...	Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von ...	Multiple Sclerosis;Autonomic Nervous System Dysfunction	Drug: Gilenya	Jochen Vehoff	NULL	Completed	18 Years	60 Years	All	33	Phase 4	Switzerland
5	EUCTR2007-002627-32-CZ (EUCTR)	04/02/2009	09/04/2008	efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis	A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the effi ...	Primary progressive multiple sclerosis. MedDRA version: 17.1;Level: PT;Classification code 10063401; ...	Trade Name: Gilenya Product Name: Fingolimod Product Code: FTY720D INN or Proposed INN: Fingolimod Other ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	970		Finland;Spain;Ireland;Turkey;Russian Federation;Israel;Italy;Switzerland;United Kingdom;France;Hunga ...
6	NCT00731692 (ClinicalTrials.gov)	July 28, 2008	7/8/2008	This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Mu ...	A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Effi ...	Primary Progressive Multiple Sclerosis	Drug: FTY720;Drug: Placebo	Novartis Pharmaceuticals	NULL	Terminated	25 Years	65 Years	All	970	Phase 3	United States;Australia;Belgium;Canada;Czechia;Denmark;Finland;France;Germany;Hungary;Italy;Netherla ...

First Previous1Next Last